Announced Thu, 9 Jul · 15:50 IST
Routine RTA compliance certificate for Q1 FY27 filed with BSE
Compliance View source PDF
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+2.4%1-day move
₹21.97
prior close
—
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
————+2.4-2.2-1.5-3.0+1.0-2.2————
Up moveDown movePending
AI summary
Kabra Drugs has submitted a quarterly compliance certificate to BSE under SEBI Regulation 74(5) for the quarter ended 30 June 2026. The certificate, issued by its Registrar and Share Transfer Agent Skyline Financial Services, confirms that physical share certificates received for dematerialization were listed on the exchange, verified, cancelled, and replaced by the depository as the registered owner within 15 days.
Likely market impact
Routine regulatory compliance filing with no material impact on operations or shareholders.